<p>随着全球市场继续应对地缘政治紧张局势和经济变化，亚洲股票因其增长潜力而吸引了投资者的关注。在这种环境下，识别那些可能低于其公允价值交易的股票，可以为寻求利用市场低效的投资者提供机会。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>中基光电 (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>浙江杰美电子科技 (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>苏宁易购 (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD 可再生能源 (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>国全食品 (上海) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes 科技 (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma 控股 (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 258 只被低估亚洲股票的完整列表。</p>
<p>我们将从我们的筛选结果中选取一些进行分析。</p>
<h2>南京诺唯赞生物科技 (SHSE:688105)</h2>
<p><strong>概述：</strong> 南京诺唯赞生物科技有限公司提供生命科学、生物医学和体外诊断领域的技术解决方案，市值为 88.7 亿人民币。</p>
<p><strong>运营：</strong> 南京诺唯赞生物科技有限公司通过其在生命科学、生物医学和体外诊断领域的技术解决方案产生收入。</p>
<p><strong>公允价值折扣估算：</strong> 32.6%</p>
<p>南京诺唯赞生物科技的交易价格为 22.3 元，显著低于其估算公允价值 33.06 元，表明其基于现金流被低估。尽管截至 2025 年 9 月的九个月内净收入下降至 662 万元，但预计未来三年内收益将年均增长超过 80%，超出市场平均水平。然而，1.35% 的股息收益率缺乏收益或自由现金流的覆盖。</p>
<ul>
<li>我们最近的增长报告指出，南京诺唯赞生物科技的商业前景乐观。</li>
<li>点击这里阅读我们的健康报告，深入了解南京诺唯赞生物科技的资产负债表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688105 截至 2026 年 1 月的折现现金流</p>
<h2>安徽容知日新科技 (SHSE:688768)</h2>
<p><strong>概述：</strong> 安徽容知日新科技有限公司在中国提供预测性维护领域的机械状态监测解决方案，市值为 44.7 亿人民币。</p>
<p><strong>运营：</strong> 安徽容知日新科技通过提供机械状态监测解决方案在预测性维护行业中产生收入。</p>
<p><strong>公允价值折扣估算：</strong> 45.1%</p>
<p>安徽容知日新科技的交易价格为 50.81 元，显著低于其估算公允价值 92.54 元，突显其基于现金流的被低估。该公司截至 2025 年 9 月的九个月内净收入为 2690 万元，较去年大幅增长。预计收益将年均增长超过 30%，超出市场平均水平，尽管股息稳定性仍然是一个问题，且历史记录不稳定。</p>
<ul>
<li>我们编制的增长报告表明，安徽容知日新科技的未来前景可能向好。</li>
<li>点击这里查看我们报告中安徽容知日新科技的资产负债表健康状况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688768 截至 2026 年 1 月的折现现金流</p>
<h2>贝克伦 (TSE:6532)</h2>
<p><strong>概述：</strong> 贝克伦公司在日本提供咨询服务，市值约为 10.4 亿日元。</p>
<p><strong>运营：</strong> 该公司通过其咨询业务部门产生收入，金额为 1.3042 亿日元。</p>
<p><strong>公允价值折扣估算：</strong> 34.5%</p>
<p>贝克伦的交易价格为 6828 日元，显著低于其估算公允价值 10424.18 日元，突显其基于现金流的被低估。预计该公司的收益在未来三年将年均增长超过 20%，超出市场平均水平。尽管与收益相比，收入增长预测较慢，但贝克伦的股本回报率仍然强劲。最近的领导层变动和股息增加可能会影响投资者情绪，但不会改变其基本估值吸引力。</p>
<ul>
<li>我们的收益增长报告揭示了贝克伦未来业绩显著增长的潜力。</li>
<li>点击这里探索我们在贝克伦资产负债表健康报告中的详细分析。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TSE:6532 截至 2026 年 1 月的折现现金流</p>
<h2>让它发生</h2>
<ul>
<li>开始您的投资之旅，查看我们基于现金流的 258 只被低估亚洲股票的选择。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并利用我们的综合分析工具获取见解。</li>
<li>利用 Simply Wall St 掌控您的财务未来，为每位投资者提供国际市场的免费深入知识。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健股息支付者来多样化您的投资组合，以应对潜在的市场波动。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章性质较为一般。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

诺唯赞

容知日新

<p>被认为可能被低估的三只亚洲股票包括：安徽容知日新，当前交易价格为 50.81 元，较其公允价值 92.54 元有 45.1% 的折扣；南京诺唯赞生物科技，当前交易价格为 22.3 元，较其公允价值 33.06 元有 32.6% 的折扣；以及 Baycurrent，当前交易价格为 6,828 日元，较其公允价值 10,424.18 日元有 34.5% 的折扣。这些公司在当前市场环境下展现出良好的增长潜力，使其成为寻求被低估投资机会的投资者的吸引对象</p>

<p>As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities are capturing investor attention with their potential for growth. In this environment, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on market inefficiencies.</p>
<div class="lb-trans"><p>随着全球市场继续应对地缘政治紧张局势和经济变化，亚洲股票因其增长潜力而吸引了投资者的关注。在这种环境下，识别那些可能低于其公允价值交易的股票，可以为寻求利用市场低效的投资者提供机会。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Zhongji Innolight (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>Zhejiang Jiemei Electronic And Technology (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>Suning.com (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD Renewable Energy (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>Guoquan Food (Shanghai) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>中基光电 (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>浙江杰美电子科技 (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>苏宁易购 (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD 可再生能源 (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>国全食品 (上海) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes 科技 (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma 控股 (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 258 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 258 只被低估亚洲股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我们将从我们的筛选结果中选取一些进行分析。</p>
</div><h2>Nanjing Vazyme Biotech (SHSE:688105)</h2>
<div class="lb-trans"><h2>南京诺唯赞生物科技 (SHSE:688105)</h2>
</div><p><strong>Overview:</strong> Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics, with a market cap of CN¥8.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 南京诺唯赞生物科技有限公司提供生命科学、生物医学和体外诊断领域的技术解决方案，市值为 88.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in the fields of life science, biomedicine, and in vitro diagnostics.</p>
<div class="lb-trans"><p><strong>运营：</strong> 南京诺唯赞生物科技有限公司通过其在生命科学、生物医学和体外诊断领域的技术解决方案产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 32.6%</p>
</div><p>Nanjing Vazyme Biotech is trading at CNY 22.3, significantly below its estimated fair value of CNY 33.06, indicating it is undervalued based on cash flows. Despite a recent decrease in net income to CNY 6.62 million for the nine months ended September 2025, earnings are projected to grow substantially by over 80% annually and surpass average market growth within three years. However, the dividend yield of 1.35% lacks coverage by earnings or free cash flow.</p>
<div class="lb-trans"><p>南京诺唯赞生物科技的交易价格为 22.3 元，显著低于其估算公允价值 33.06 元，表明其基于现金流被低估。尽管截至 2025 年 9 月的九个月内净收入下降至 662 万元，但预计未来三年内收益将年均增长超过 80%，超出市场平均水平。然而，1.35% 的股息收益率缺乏收益或自由现金流的覆盖。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Nanjing Vazyme Biotech's business outlook.</li>
<li>Get an in-depth perspective on Nanjing Vazyme Biotech's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们最近的增长报告指出，南京诺唯赞生物科技的商业前景乐观。</li>
<li>点击这里阅读我们的健康报告，深入了解南京诺唯赞生物科技的资产负债表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf?theme=light"/></p>
<p>SHSE:688105 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688105 截至 2026 年 1 月的折现现金流</p>
</div><h2>Anhui Ronds Science &amp; Technology (SHSE:688768)</h2>
<div class="lb-trans"><h2>安徽容知日新科技 (SHSE:688768)</h2>
</div><p><strong>Overview:</strong> Anhui Ronds Science &amp; Technology Incorporated Company offers solutions for machinery condition monitoring in the predictive maintenance sector in China, with a market cap of CN¥4.47 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 安徽容知日新科技有限公司在中国提供预测性维护领域的机械状态监测解决方案，市值为 44.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Anhui Ronds Science &amp; Technology generates its revenue from providing solutions for machinery condition monitoring within the predictive maintenance industry in China.</p>
<div class="lb-trans"><p><strong>运营：</strong> 安徽容知日新科技通过提供机械状态监测解决方案在预测性维护行业中产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 45.1%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 45.1%</p>
</div><p>Anhui Ronds Science &amp; Technology is trading at CN¥50.81, significantly below its estimated fair value of CN¥92.54, highlighting its undervaluation based on cash flows. The company reported net income of CN¥26.9 million for the nine months ended September 2025, a substantial increase from the previous year. Earnings are forecast to grow significantly by over 30% annually, outpacing market averages, though dividend stability remains a concern with an unstable track record.</p>
<div class="lb-trans"><p>安徽容知日新科技的交易价格为 50.81 元，显著低于其估算公允价值 92.54 元，突显其基于现金流的被低估。该公司截至 2025 年 9 月的九个月内净收入为 2690 万元，较去年大幅增长。预计收益将年均增长超过 30%，超出市场平均水平，尽管股息稳定性仍然是一个问题，且历史记录不稳定。</p>
</div><ul>
<li>The growth report we've compiled suggests that Anhui Ronds Science &amp; Technology's future prospects could be on the up.</li>
<li>Take a closer look at Anhui Ronds Science &amp; Technology's balance sheet health here in our report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，安徽容知日新科技的未来前景可能向好。</li>
<li>点击这里查看我们报告中安徽容知日新科技的资产负债表健康状况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf?theme=light"/></p>
<p>SHSE:688768 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688768 截至 2026 年 1 月的折现现金流</p>
</div><h2>Baycurrent (TSE:6532)</h2>
<div class="lb-trans"><h2>贝克伦 (TSE:6532)</h2>
</div><p><strong>Overview:</strong> Baycurrent, Inc. offers consulting services in Japan and has a market cap of approximately ¥1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 贝克伦公司在日本提供咨询服务，市值约为 10.4 亿日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Consulting Business segment, which amounts to ¥130.42 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其咨询业务部门产生收入，金额为 1.3042 亿日元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 34.5%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 34.5%</p>
</div><p>Baycurrent is trading at ¥6,828, notably below its estimated fair value of ¥10,424.18, underscoring its undervaluation based on cash flows. The company's earnings are projected to grow over 20% annually for the next three years, surpassing market averages. Despite slower revenue growth forecasts compared to earnings, Baycurrent's return on equity remains robust. Recent leadership changes and dividend increases may impact investor sentiment but don't alter the fundamental valuation appeal.</p>
<div class="lb-trans"><p>贝克伦的交易价格为 6828 日元，显著低于其估算公允价值 10424.18 日元，突显其基于现金流的被低估。预计该公司的收益在未来三年将年均增长超过 20%，超出市场平均水平。尽管与收益相比，收入增长预测较慢，但贝克伦的股本回报率仍然强劲。最近的领导层变动和股息增加可能会影响投资者情绪，但不会改变其基本估值吸引力。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in Baycurrent's future results.</li>
<li>Click to explore a detailed breakdown of our findings in Baycurrent's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的收益增长报告揭示了贝克伦未来业绩显著增长的潜力。</li>
<li>点击这里探索我们在贝克伦资产负债表健康报告中的详细分析。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf?theme=light"/></p>
<p>TSE:6532 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>TSE:6532 截至 2026 年 1 月的折现现金流</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Embark on your investment journey to our 258 Undervalued Asian Stocks Based On Cash Flows selection here.</li>
<li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li>
<li>Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.</li>
</ul>
<div class="lb-trans"><ul>
<li>开始您的投资之旅，查看我们基于现金流的 258 只被低估亚洲股票的选择。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并利用我们的综合分析工具获取见解。</li>
<li>利用 Simply Wall St 掌控您的财务未来，为每位投资者提供国际市场的免费深入知识。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健股息支付者来多样化您的投资组合，以应对潜在的市场波动。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章性质较为一般。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

3 只亚洲股票可能以低于公允价值最多 45.1% 的价格进行交易